Turkey Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Turkey Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Turkey Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: A strong health care sector and more certain drug pricing policy will drive pharmaceutical sales in value terms over the next 10 years and improve the commercial opportunities for pharmaceutical manufacturers. Despite this positive development, cost containment measures will remain a risk, as will the political situation with neighbouring Syria and nearby Russia .

Headline Expenditure Projections

  • Pharmaceuticals: TRY18.72bn (USD8.56bn) in 2014 to TRY20.81bn (USD7.38bn) in 2015; +11.1% in local currency and -13.8% US dollar terms. Forecast unchanged in local curren cy and down in US dollars compared with previous quarter due to revised exchange rate expectations.

  • Healthcare: TRY95.78bn (USD43.78bn) in 2014 to TRY107.17bn (USD38.01bn) in 2015; +11.9% in local currency and -13.2% US dollar terms. Forecast unchanged in local currency and down in US dollars compared with previous quarter due to revised exchange rate expectations.

Headline Pharmaceuticals & Healthcare Forecasts (Turkey 2013-2019)
2013 2014 2015f 2016f 2017f 2018f 2019f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 9.126 8.559 7.379 7.313 7.834 8.451 9.175
Pharmaceutical sales, % of GDP 1.11 1.07 1.08 1.08 1.08 1.08 1.09
Pharmaceutical sales, % of health expenditure 19.9 19.5 19.4 19.4 19.4 19.4 19.4
Health spending, USDbn 45.913 43.782 38.005 37.631 40.305 43.495 47.267

Risk/Reward Index

Turkey's Pharmaceutical Risk/Reward Index score for Q116 is 54.7, up from a score of 52.3 in the previous quarter on the back of an improved rating in the 'Rewards' category. The country is ranked the seventh most attractive business environment out of the 20 markets surveyed in Emerging Europe. Turkey's large drug market, coupled with the sector's long-term growth potential, means the country scores higher than the average for the region on this indicator. In terms of risks, several rounds of pricing reforms mean the country scores less favourably, and below the regional average for this indicator.

Key Trends and Developments

  • In November 2015, Turkey's PM Ahmet Davutoglu revealed a comprehensive plan to enhance the country's economy through the implementation of wide-ranging structural reforms in various sectors, including healthcare. A government committee will monitor the proper implementation of the plan, Davutoglu noted. The reform plan includes: decreasing import dependence, commercialisation in primary technology areas, structural transformation in healthcare industries, and increasing health tourism.

  • In October 2015, the World Bank praised Turkey for its healthcare reforms in its 'Going Universal' report. The report highlighted that an advanced quality assurance system offered by Turkey's health ministry has helped to control out-of-pocket expenditure in the country. Turkey is among the developing countries where out-of-pocket expenditure for healthcare is relatively low.

BMI Economic View

Turkish real GDP surprised to the upside once again in Q315 with 4.0% y-o-y growth compared to Bloomberg consensus estimates of 2.7%, prompting us to revise up our 2015 GDP forecast from 2.8% to 3.3%. That said, the composition of growth remains skewed heavily towards consumption, supporting our view that Turkey's external rebalancing will grind to a halt in 2016 with the current account deficit still hovering around 5.0% of GDP. Combined with elevated policy risks, external headwinds and a mounting domestic debt overhang, the challenges facing the economy in the coming year remain prominent.

BMI Political View

A decisive victory for Turkey's Justice and Development Party (AKP) in the November 1 snap election has been positive for the short-term growth outlook. Reduced political uncertainty is reflected in a strong bounce in the November consumer and business confidence reading, which will support consumption and investment in the coming months. However, a return to single-party rule under the AKP is no panacea as significant macro headwinds and policy risks lie ahead on various fronts.

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Operational Risk
14
Industry Forecast
16
Pharmaceutical Market Forecast
16
Table: Pharmaceutical Sales, Historical Data And Forecasts (Turkey 2011-2019)
18
Healthcare Market Forecast
19
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019)
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019)
21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019)
21
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019)
23
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019)
25
Generic Drug Market Forecast
26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019)
27
OTC Medicine Market Forecast
28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Turkey 2011-2019)
30
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecasts (Turkey 2013-2019)
32
Table: Pharmaceutical Trade Data And Forecasts - Local Currency (Turkey 2013-2019)
33
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
35
Economic Analysis
35
Table: Economic Activity (Turkey 2010-2019)
44
Industry Risk/Reward Indices
45
Central And Eastern Europe Risk/Reward Index - Q4 2015
45
Turkey Risk/Reward Index
51
Rewards
51
Risks
52
Market Overview
54
Industry Trends And Developments
55
Epidemiology
55
Healthcare Sector
57
Healthcare Insurance
57
Healthcare Infrastructure
58
Healthcare Financing
60
Table: Healthcare Resources (Turkey 2009-2014)
61
Table: Healthcare Personnel (Turkey 2009-2014)
61
Table: Healthcare Activity (Turkey 2009-2014)
62
Research & Development
62
Clinical Trials
64
Regulatory Development
65
Intellectual Property Regime
66
Market Access Issues
69
Pricing Regime
71
Table: Turkish Pharmaceutical Pricing Decrees
72
Reimbursement Regime
73
Table: Pharmacist Discount Related To Annual Sales Revenue (VAT Excluded)
75
Competitive Landscape
76
Pharmaceutical Sector
76
Research-Based Industry
77
Generic Drugmakers
78
Company Activity
79
Pharmaceutical Distribution
80
Pharmaceutical Retail
81
Company Profile
83
Abdi -brahim
83
Bayer
87
EastPharma (Deva)
89
Eczaciba-i Healthcare
92
GlaxoSmithKline
95
Mustafa Nevzat Ilac Sanayi (MN) Pharmaceuticals
98
Novartis
101
Pfizer
103
Roche
106
Sanofi
109
Sanovel Pharmaceuticals
112
Demographic Forecast
115
Table: Population Headline Indicators (Turkey 1990-2025)
116
Table: Key Population Ratios (Turkey 1990-2025)
116
Table: Urban/Rural Population & Life Expectancy (Turkey 1990-2025)
117
Table: Population By Age Group (Turkey 1990-2025)
117
Table: Population By Age Group % (Turkey 1990-2025)
118
Glossary
120
Methodology
122
Pharmaceutical Expenditure Forecast Model
122
Healthcare Expenditure Forecast Model
122
Notes On Methodology
123
Risk/Reward Index Methodology
124
Index Overview
125
Table: Pharmaceutical Risk/Reward Index Indicators
125
Indicator Weightings
126

The Turkey Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Turkey Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Turkey pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Turkey, to test other views - a key input for successful budgeting and strategic business planning in the Turkish pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Turkish pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Turkey.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.